Tumor-associated Macrophages and Anti-tumor Therapies: Complex Links

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2016 Mar 10

PMID 26956893

Citations 65

Authors

Cristina Belgiovine

Maurizio DIncalci

Paola Allavena

Roberta Frapolli

Affiliations

Soon will be listed here.

Abstract

Myeloid cells infiltrating the tumor microenvironment, especially tumor-associated macrophages (TAMs), are essential providers of cancer-related inflammation, a condition known to accelerate tumor progression and limit the response to anti-tumor therapies. As a matter of fact, TAMs may have a dual role while interfering with cancer treatments, as they can either promote or impair their functionality. Here we review the connection between macrophages and anticancer therapies; moreover, we provide an overview of the different strategies to target or re-program TAMs for therapeutic purposes.

Citing Articles

Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.

Tapiainen V, Sirnio P, Elomaa H, Karjalainen H, Aijala V, Kastinen M Br J Cancer. 2025; .

PMID: 40055484 DOI: 10.1038/s41416-025-02972-z.

Exploring the Role of Macrophages and Their Associated Structures in Rheumatoid Arthritis.

Tian X, Chen J, Hong Y, Cao Y, Xiao J, Zhu Y J Innate Immun. 2025; 17(1):95-111.

PMID: 39938504 PMC: 11820663. DOI: 10.1159/000543444.

Different subpopulations of macrophages, neutrophils, mast cells, and fibroblasts are involved in the control of tumor angiogenesis.

Ribatti D Front Med (Lausanne). 2024; 11:1481609.

PMID: 39440039 PMC: 11495228. DOI: 10.3389/fmed.2024.1481609.

A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma.

Qin L, Li Y, Zeng R, He Y, Chen X, Xiao L Hum Vaccin Immunother. 2024; 20(1):2408088.

PMID: 39348228 PMC: 11445887. DOI: 10.1080/21645515.2024.2408088.

Activated THP-1 Macrophage-Derived Factors Increase the Cytokine, Fractalkine, and EGF Secretions, the Invasion-Related MMP Production, and Antioxidant Activity of HEC-1A Endometrium Cells.

Pandur E, Pap R, Sipos K Int J Mol Sci. 2024; 25(17).

PMID: 39273575 PMC: 11395051. DOI: 10.3390/ijms25179624.

References

Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

Luo Y, Knudson M . Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol. 2010; 2010:357591. PMC: 2939389. DOI: 10.1155/2010/357591. View

Moreau M, Guillet C, Massin P, Chevalier S, Gascan H, Basle M . Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2006; 73(5):718-23. DOI: 10.1016/j.bcp.2006.09.031. View

Martinez-Pomares L, Reid D, Brown G, Taylor P, Stillion R, Linehan S . Analysis of mannose receptor regulation by IL-4, IL-10, and proteolytic processing using novel monoclonal antibodies. J Leukoc Biol. 2003; 73(5):604-13. DOI: 10.1189/jlb.0902450. View

Zhang W, Gordon M, Schultheis A, Yang D, Nagashima F, Azuma M . FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007; 25(24):3712-8. DOI: 10.1200/JCO.2006.08.8021. View

Zhang W, Zhu X, Sun H, Xiong Y, Zhuang P, Xu H . Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010; 16(13):3420-30. DOI: 10.1158/1078-0432.CCR-09-2904. View

Jia J, Wang W, Sun H, Zhu X, Liu L, Zhuang P . High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist. 2010; 15(7):732-43. PMC: 3228006. DOI: 10.1634/theoncologist.2009-0170. View

Guo C, Buranych A, Sarkar D, Fisher P, Wang X . The role of tumor-associated macrophages in tumor vascularization. Vasc Cell. 2013; 5(1):20. PMC: 3913793. DOI: 10.1186/2045-824X-5-20. View

10.

Jaiswal S, Chao M, Majeti R, Weissman I . Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010; 31(6):212-9. PMC: 3646798. DOI: 10.1016/j.it.2010.04.001. View

11.

Ferrara N . Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol. 2010; 17(3):219-24. DOI: 10.1097/MOH.0b013e3283386660. View

12.

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S . Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010; 70(6):2235-44. DOI: 10.1158/0008-5472.CAN-09-2335. View

13.

DIncalci M, Badri N, Galmarini C, Allavena P . Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014; 111(4):646-50. PMC: 4134488. DOI: 10.1038/bjc.2014.149. View

14.

Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C . Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 2014; 74(17):4706-19. DOI: 10.1158/0008-5472.CAN-13-3334. View

15.

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

16.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

17.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A . Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19(4):512-26. DOI: 10.1016/j.ccr.2011.02.005. View

18.

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

19.

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

20.

Furness A, Vargas F, Peggs K, Quezada S . Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014; 35(7):290-8. DOI: 10.1016/j.it.2014.05.002. View